Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis.
Anemia
Cirrhosis
Hypersplenism
Portal hypertension
TIPS
Thrombocytopenia
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
23
06
2021
accepted:
07
02
2022
pubmed:
19
3
2022
medline:
16
11
2022
entrez:
18
3
2022
Statut:
ppublish
Résumé
Patients with cirrhosis often develop portal hypertension-associated splenomegaly and hypersplenism, potentially causing severe cytopenia. Systematic assessment on the impact of transjugular intrahepatic portosystemic shunt (TIPS) implantation on platelet count (PLT), hemoglobin (Hb), and white blood cell count (WBC). Patients with cirrhosis undergoing covered TIPS implantation were retrospectively included. Patients with malignancies or hematologic disorders were excluded. Hematology lab work was recorded at baseline (pre-TIPS) and at regular intervals after TIPS. One hundred ninety-two patients (male: 72.4%, age: 56 ± 10 years; MELD: 12.1 ± 3.6) underwent TIPS implantation. Higher-grade (≥ G2) thrombocytopenia (PLT < 100 G/L) was present in 54 (28.7%), ≥ G2 anemia (Hb < 10 g/dL) in 57 (29.7%), and ≥ G2 leukopenia (WBC < 2 G/L) in 3 (1.6%) patients pre-TIPS, respectively. Resolution of ≥ G2 thrombocytopenia, anemia, and leukopenia occurred in 24/55 (43.6%), 23/57 (40.4%), and 2/3 (66.7%), respectively. Similar results were also observed in the subgroup of patients without 'bleeding' TIPS-indication, with improvements of G ≥ 2 thrombocytopenia and of G ≥ 2 anemia in 19.8% and 10.2% of patients after TIPS, respectively. Thrombocytopenia, anemia, and leukopenia frequently improved after TIPS. Therefore, moderate- to higher-grade thrombocytopenia should not be regarded as a contraindication against TIPS, but rather be considered in case of severe thrombocytopenia-particularly prior to surgery or interventions.
Sections du résumé
BACKGROUND
Patients with cirrhosis often develop portal hypertension-associated splenomegaly and hypersplenism, potentially causing severe cytopenia.
AIMS
Systematic assessment on the impact of transjugular intrahepatic portosystemic shunt (TIPS) implantation on platelet count (PLT), hemoglobin (Hb), and white blood cell count (WBC).
METHODS
Patients with cirrhosis undergoing covered TIPS implantation were retrospectively included. Patients with malignancies or hematologic disorders were excluded. Hematology lab work was recorded at baseline (pre-TIPS) and at regular intervals after TIPS.
RESULTS
One hundred ninety-two patients (male: 72.4%, age: 56 ± 10 years; MELD: 12.1 ± 3.6) underwent TIPS implantation. Higher-grade (≥ G2) thrombocytopenia (PLT < 100 G/L) was present in 54 (28.7%), ≥ G2 anemia (Hb < 10 g/dL) in 57 (29.7%), and ≥ G2 leukopenia (WBC < 2 G/L) in 3 (1.6%) patients pre-TIPS, respectively. Resolution of ≥ G2 thrombocytopenia, anemia, and leukopenia occurred in 24/55 (43.6%), 23/57 (40.4%), and 2/3 (66.7%), respectively. Similar results were also observed in the subgroup of patients without 'bleeding' TIPS-indication, with improvements of G ≥ 2 thrombocytopenia and of G ≥ 2 anemia in 19.8% and 10.2% of patients after TIPS, respectively.
CONCLUSIONS
Thrombocytopenia, anemia, and leukopenia frequently improved after TIPS. Therefore, moderate- to higher-grade thrombocytopenia should not be regarded as a contraindication against TIPS, but rather be considered in case of severe thrombocytopenia-particularly prior to surgery or interventions.
Identifiants
pubmed: 35301618
doi: 10.1007/s10620-022-07443-6
pii: 10.1007/s10620-022-07443-6
pmc: PMC9652242
doi:
Substances chimiques
Hemoglobins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5693-5703Informations de copyright
© 2022. The Author(s).
Références
AJR Am J Roentgenol. 1992 Aug;159(2):317-20
pubmed: 1632346
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
J Hepatol. 2015 Nov;63(5):1272-84
pubmed: 26192220
Gastroenterol Rep (Oxf). 2016 Oct 2;5(4):305-308
pubmed: 27694618
Liver Int. 2018 Jun;38(6):1036-1044
pubmed: 29091351
N Engl J Med. 2010 Jun 24;362(25):2370-9
pubmed: 20573925
Expert Rev Gastroenterol Hepatol. 2013 Feb;7(2):141-55
pubmed: 23363263
J Clin Ultrasound. 2000 Sep;28(7):332-9
pubmed: 10934332
Dig Liver Dis. 2017 Dec;49(12):1360-1367
pubmed: 28869158
Wien Klin Wochenschr. 2013 Apr;125(7-8):200-19
pubmed: 23579878
Trop Doct. 1997 Apr;27(2):114-5
pubmed: 9133805
Wien Klin Wochenschr. 2020 Jan;132(1-2):1-11
pubmed: 31912289
Clin Liver Dis. 2021 May;25(2):291-310
pubmed: 33838851
World J Surg. 2010 Feb;34(2):320-6
pubmed: 20012612
Hepatology. 2019 Oct;70(4):1336-1348
pubmed: 30762895
Liver Int. 2020 Jan;40(1):194-204
pubmed: 31444993
Gastroenterol Hepatol (N Y). 2017 May;13(5):286-291
pubmed: 28656025
Wien Klin Wochenschr. 2017 Nov;129(Suppl 3):135-158
pubmed: 29063233
J Hepatol. 2017 Feb;66(2):442-450
pubmed: 27984174
J Hepatol. 2011 May;54(5):901-7
pubmed: 21145798
Cell Biochem Biophys. 2014 Sep;70(1):355-60
pubmed: 24696075
Liver Int. 2017 Jun;37(6):778-793
pubmed: 27860293
World J Gastroenterol. 2019 Jan 21;25(3):308-329
pubmed: 30686900
Gut. 2020 Aug;69(8):1535-1536
pubmed: 31270166
Liver Int. 2019 Feb;39(2):290-298
pubmed: 30248224
Dig Dis Sci. 2012 Sep;57(9):2430-7
pubmed: 22588242
World J Gastroenterol. 2014 Mar 14;20(10):2595-605
pubmed: 24627595
J Lab Clin Med. 2001 Nov;138(5):332-7
pubmed: 11709657
PLoS One. 2018 Jan 9;13(1):e0189414
pubmed: 29315304
Gut. 2021 Feb;70(2):379-387
pubmed: 32241903
J Hepatol. 2021 Apr;74(4):819-828
pubmed: 33075344
Aust N Z J Med. 1990 Dec;20(6):771-4
pubmed: 2291725
Exp Biol Med (Maywood). 2017 Apr;242(7):744-749
pubmed: 28299974
Clin Liver Dis. 2021 May;25(2):419-430
pubmed: 33838858
Hepatology. 2018 Apr;67(4):1472-1484
pubmed: 29059466
J Hepatol. 2020 Nov;73(5):1082-1091
pubmed: 32339602
Dig Liver Dis. 2009 Jun;41(6):411-6
pubmed: 19070555
Clin Gastroenterol Hepatol. 2009 Jun;7(6):689-95
pubmed: 19281860
Gut. 2021 Sep;70(9):1758-1767
pubmed: 33199442
J Hepatol. 2021 Mar;74(3):670-685
pubmed: 33301825
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
J Hepatol. 2013 May;58(5):911-21
pubmed: 23262249
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):587-598
pubmed: 31153882
AJR Am J Roentgenol. 2021 Mar;216(3):698-703
pubmed: 33439047
J Hepatol. 1999 Feb;30(2):254-9
pubmed: 10068105
Liver Int. 2020 Apr;40(4):988-989
pubmed: 31612610
AJR Am J Roentgenol. 2008 Jul;191(1):W8-W16
pubmed: 18562713
Gastroenterology. 2013 Jan;144(1):102-111.e1
pubmed: 23058320